Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements
Authors
Keywords
-
Journal
Drug Design Development and Therapy
Volume Volume 15, Issue -, Pages 159-170
Publisher
Informa UK Limited
Online
2021-01-13
DOI
10.2147/dddt.s287323
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics
- (2020) DavidS. Collins et al. JOURNAL OF CONTROLLED RELEASE
- Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge
- (2020) Manuel Sánchez-Félix et al. ADVANCED DRUG DELIVERY REVIEWS
- Multiscale simulations of drug distributions in polymer dissolvable microneedles
- (2020) Yun Hao Feng et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- A basal-bolus insulin regimen integrated microneedle patch for intraday postprandial glucose control
- (2020) Bo Zhi Chen et al. Science Advances
- Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden
- (2019) Elham Hedayati et al. PLoS One
- ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20
- (2019) Kenneth W. Locke et al. DRUG DELIVERY
- Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases
- (2019) Fernanda P. Pons-Faudoa et al. BIOMEDICAL MICRODEVICES
- Subcutaneous Delivery of Daratumumab in Relapsed or Refractory Multiple Myeloma
- (2019) Saad Z. Usmani et al. BLOOD
- Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES)
- (2019) Ajai Chari et al. Clinical Lymphoma Myeloma & Leukemia
- Insulin delivery systems combined with microneedle technology
- (2018) Xuan Jin et al. ADVANCED DRUG DELIVERY REVIEWS
- N032 Impact of pain due to subcutaneous administration of a biological drug
- (2018) C Gely et al. Journal of Crohns & Colitis
- Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins
- (2018) Michael R. Turner et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Pressure and stress transients in autoinjector devices
- (2018) Jean-Christophe Veilleux et al. Drug Delivery and Translational Research
- Non-invasive delivery strategies for biologics
- (2018) Aaron C. Anselmo et al. NATURE REVIEWS DRUG DISCOVERY
- High-concentration protein formulations: How high is high?
- (2017) Patrick Garidel et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins
- (2017) Lora Hamuro et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Subcutaneous drug delivery: An evolving enterprise
- (2017) Graham B. Jones et al. Science Translational Medicine
- The number of injected same-day preschool vaccines relates to preadolescent needle fear and HPV uptake
- (2017) Amy L. Baxter et al. VACCINE
- Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)
- (2016) M. Rummel et al. ANNALS OF ONCOLOGY
- Understanding Subcutaneous Tissue Pressure for Engineering Injection Devices for Large-Volume Protein Delivery
- (2016) Diane V. Doughty et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Subcutaneous Injection Volume of Biopharmaceuticals—Pushing the Boundaries
- (2016) Roman Mathaes et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- A novel electromechanical autoinjector, AutoTouch™, for self-injection of etanercept: real-world use and benefits
- (2016) David H. Collier et al. POSTGRADUATE MEDICINE
- Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects
- (2015) Clapton Dias et al. AAPS PHARMSCITECH
- Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study
- (2015) L. Fallowfield et al. BREAST
- Facilitated subcutaneous immunoglobulin (fSCIg) therapy - practical considerations
- (2015) M. Ponsford et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Subcutaneous Trastuzumab for HER2-positive Breast Cancer – Evidence and Practical Experience in 7 German Centers
- (2015) C. Jackisch et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- A snapshot of biologic drug development
- (2015) L Andrews et al. HUMAN & EXPERIMENTAL TOXICOLOGY
- Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
- (2014) X. Pivot et al. ANNALS OF ONCOLOGY
- Preference for Rituximab Subcutaneous (Sc) and Intravenous (Iv) Among Patients With Cd20+ Non-Hodgkin's Lymphoma (Nhl) Completing the Rasq Measure In Randomized Phase Iii Studies Prefmab and Mabcute
- (2014) S. Rule et al. VALUE IN HEALTH
- Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom
- (2014) Simon Rule et al. JOURNAL OF MEDICAL ECONOMICS
- Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20
- (2013) Peter N. Morcos et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
- (2013) Xavier Pivot et al. LANCET ONCOLOGY
- Strategies for non-invasive delivery of biologics
- (2012) Seung Woo Chung et al. JOURNAL OF DRUG TARGETING
- Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
- (2012) A. Martin et al. TRANSFUSION MEDICINE
- Reduction in Intrasubject Variability in the Pharmacokinetic Response to Insulin After Subcutaneous Co-Administration with Recombinant Human Hyaluronidase in Healthy Volunteers
- (2011) Linda Morrow et al. Diabetes Technology & Therapeutics
- Development of high concentration protein biopharmaceuticals: The use of platform approaches in formulation development
- (2011) Nicholas W. Warne EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started